Global Computer Vision in Healthcare Market Trends, 2031

Computer vision in healthcare uses machine learning models to interpret images and video, including X-rays, computed tomography and magnetic resonance scans, ultrasound, pathology slides, retinal photographs, skin images, endoscopy video and camera feeds in wards and operating rooms. Typical tasks are detecting and measuring abnormalities, prioritising urgent cases in a radiology worklist, counting cells, segmenting organs for treatment planning, guiding instruments during surgery and monitoring patient movement or falls. Most products are sold as software that sits inside picture archiving systems, scanners or cloud workflows, and many are regulated as medical devices. Radiology dominates, with roughly three quarters of the United States Food and Drug Administration's authorised artificial intelligence devices serving imaging specialities, followed by cardiology, neurology, pathology and ophthalmology. Competition includes imaging equipment makers such as GE HealthCare, Siemens Healthineers and Philips, platform firms such as NVIDIA and large cloud providers, and specialist vendors such as Aidoc, Viz.ai, Paige, HeartFlow and Qure.ai. Typical contracts are annual subscriptions or per-study fees, and buyers value evidence of accuracy across patient groups and scanner types. The field is shifting from single-purpose detection tools to broader platforms and foundation models that can read several findings in one study, draft reports and combine images with clinical notes. At the same time, regulators are building lifecycle rules. The Food and Drug Administration issued final guidance on predetermined change control plans in December 2024 and proposed lifecycle guidance for artificial intelligence-enabled device software in January 2025, while the European Union has provisionally moved high-risk AI Act duties for medical devices to August 2028. Evidence quality remains a debate, because only a small fraction of authorised tools have been tested in randomised studies or tied to patient outcomes, and reimbursement is limited to a few products. For researchers, the key variables through 2031 are the pace of regulatory clearance, creation of payment pathways, adoption of foundation models and generative reporting, radiologist and pathologist workforce shortages, and the ability of vendors to prove real-world benefit and fairness across populations. Cybersecurity, data sharing agreements and clinician training will also influence how quickly hospitals can move from pilots to routine use across several sites. Drivers •Clinician Shortages and Rising Imaging Volumes: Imaging volumes grow each year as populations age and screening programmes expand, while the number of radiologists, pathologists and sonographers does not keep pace in many countries. Hospitals use computer vision to triage urgent scans such as suspected stroke or pulmonary embolism, automate measurements and reduce report turnaround. In pathology, scanning slides and applying algorithms can reduce time spent on counting and screening. Governments and providers see software as a way to extend limited expertise, particularly in rural areas and in screening programmes that handle large volumes of images. •Regulatory Pathways and Improved Algorithm Performance: A growing list of regulatory clearances gives buyers more confidence. The United States authorised well over a thousand artificial intelligence-enabled devices by early 2026, and predetermined change control plans now let manufacturers update models within agreed limits without repeated submissions. Advances in deep learning, larger training datasets and foundation models have improved detection performance and generalisation across scanners. Cloud computing and graphics processors lower the cost of running models at scale, and improved integration with imaging workflows reduces the effort needed by hospital information technology teams. Challenges •Evidence Gaps, Bias and Reimbursement: Many authorised products were cleared on retrospective data and have limited proof of improved patient outcomes, which makes hospitals cautious about paying subscription fees. Performance can fall when tools are used on different scanners, populations or clinical settings, and bias against under-represented groups is a documented concern. Reimbursement is available for only a small number of applications, so most purchases are funded from operating budgets and justified through efficiency. Without clear payment routes and prospective studies, adoption outside large academic centres can be slow and uneven. •Integration, Liability and Data Governance: Deploying several single-task algorithms from different vendors creates integration burden, alert fatigue and procurement complexity. Questions of liability remain open when a radiologist overrides or follows an algorithm, and professional bodies stress that clinicians must stay responsible. Training and monitoring models require large, well-labelled datasets that are difficult to share because of privacy law, consent and cross-border transfer limits. Cybersecurity and model drift are further risks, and hospitals need governance committees and monitoring tools, which smaller organisations struggle to maintain. Trends •Foundation Models and Generative Reporting: Developers are training large models on millions of images and reports so that one system can identify many conditions, answer questions about a scan and draft a structured report for radiologist review. Vendors are partnering with cloud and chip companies to supply computing, and some hospital groups are building their own models using internal data. Regulators are examining how to evaluate such general-purpose tools, and the Food and Drug Administration held an advisory committee on generative artificial intelligence in digital health in November 2024. Reliability, hallucination control and clear human oversight will determine how fast these tools reach clinical use. •Platforms, Edge Devices and Multimodal Care: Hospitals are moving from buying individual algorithms to orchestration platforms that host many models, route studies and monitor performance in one place. Computer vision is also moving to the edge, built into ultrasound probes, endoscopes, surgical cameras and smartphones, so that guidance happens at the point of care. Beyond radiology, applications in operating room workflow, wound measurement, ambient monitoring and remote screening are expanding, and models increasingly combine images with laboratory values, genomics and electronic health record data to support treatment choices. Software and algorithms lead because most new value comes from models that run on existing scanners and workflows, while hardware supplies the image data and services help hospitals validate, integrate and monitor tools over time. Software and algorithms form the core of the market, covering detection, segmentation, triage and quantification tools sold as subscriptions, per-study fees or bundles with imaging equipment. Their appeal is that they can run on installed scanners, picture archiving systems and cloud workflows without replacing hardware, and updates add new findings. Platforms that host several vendors' models are gaining ground because they reduce integration work. Imaging hardware and cameras include scanners, ultrasound devices, endoscopes, digital pathology scanners, surgical cameras and ward sensors, and equipment makers are embedding artificial intelligence to improve acquisition, reduce scan time and guide operators, which differentiates new systems. Hardware is also a gateway for software revenue because vendors can bundle applications with new purchases. Services include implementation, validation on local data, training, workflow redesign and ongoing performance monitoring, and demand grows as hospitals adopt governance programmes that require continuous checking for drift and bias. Dataset creation and annotation services support developers. Through 2031, software is expected to remain the largest and fastest growing component, but hardware-embedded intelligence will shape procurement as buyers prefer systems that include safe, regulated applications at purchase. Vendors increasingly sell outcome-linked packages that combine software, support and performance reporting to reduce buyer risk. Medical imaging diagnostics lead because radiology has the most digital data, the clearest workflow need and the largest number of authorised tools, while pathology, surgery, monitoring and screening are expanding from smaller bases. Medical imaging diagnostics is the largest application, spanning chest and bone radiography, mammography, computed tomography for stroke, lung nodules and bleeding, magnetic resonance for brain and prostate, ultrasound for cardiac and obstetric views, and cardiac imaging. Tools prioritise worklists, highlight findings and measure structures, saving time on routine tasks. Pathology and digital microscopy is growing as laboratories digitise slides; algorithms help detect cancer in prostate and breast biopsies, count cells and score biomarkers, although slide scanning costs remain a barrier. Surgical guidance and robotics use video analysis to recognise anatomy, track instruments, estimate blood loss and support training and quality review, and robotic platforms are adding computer vision features. Patient monitoring and safety applications use cameras and depth sensors to detect falls, bed exits, hand hygiene and distress in hospitals and care homes, subject to privacy limits. Ophthalmology and dermatology screening use photographs to detect diabetic retinopathy and skin lesions, and autonomous diabetic eye screening received United States authorisation in April 2018. By 2031, pathology and surgical applications are expected to gain share as foundation models and edge devices mature. Veterinary, dental and radiotherapy planning uses are smaller but growing, and each requires validation on its own image types and workflows. Cloud deployment leads for new software because it supplies scalable computing and easy updates, while on-premise remains common for data control and edge or embedded deployment is rising where real-time results are needed at the device. Cloud deployment is increasingly the default for new artificial intelligence services because models require graphics processors that hospitals do not wish to buy, and vendors can update algorithms, monitor performance and scale during busy periods. Radiology teleconsult groups, screening programmes and multi-site networks benefit from central processing, and major cloud providers offer medical imaging services that meet healthcare security standards. On-premise deployment remains important for hospitals that keep images within their own data centres because of privacy law, bandwidth limits, security policy or investment in existing servers, and it can deliver low latency for large studies. It demands local hardware management and slows upgrades. Edge and embedded deployment places models on scanners, ultrasound probes, endoscopy towers and smartphones, giving results within seconds without sending data away, which suits operating rooms, emergency care and low-connectivity settings. Many organisations use a hybrid pattern, running real-time tasks on the device and heavier analysis or retraining in the cloud. Through 2031, the mix is expected to move gradually towards cloud and edge, helped by regional hosting options, confidential computing and standards for federated learning that allow model training without moving raw patient images. Hospitals should compare latency, bandwidth, data transfer terms and the vendor's ability to monitor model drift across all three options. Hospitals and imaging centres lead because they generate most scans, employ the radiologists who use the tools and carry the heaviest pressure to speed reporting, while laboratories, clinics and research groups add focused demand. Hospitals and imaging centres are the largest users because they own scanners, hold picture archiving systems and employ radiologists and cardiologists who benefit from triage and measurement tools. Large academic centres adopt first and often help to test and validate products, while community hospitals use tools that address specific gaps, such as stroke detection at night. Diagnostic and pathology laboratories use computer vision for digital slides, cytology screening and quality control, and as scanning becomes routine in large networks the use of algorithms rises. Ambulatory and specialty clinics, including eye, skin, cardiology, orthopaedic and dental practices, use point-of-care tools built into devices or smartphones, and they prefer simple pricing and minimal setup. Pharmaceutical, medical technology and research organisations use computer vision to analyse trial images, quantify disease progression, discover biomarkers and test device performance, and regulators accept image-based endpoints in some studies. Government screening programmes for breast cancer, diabetic eye disease and tuberculosis are a further group of buyers. By 2031, clinics and laboratories are expected to be the fastest growing groups as lower-cost cloud services and embedded tools reduce the need for specialist information technology staff. Insurers and public health agencies that fund screening programmes are an additional and influential group, because they define evidence requirements and payment. North America is the largest region because the United States has the most imaging, the largest technology investment and the most developed regulatory pathway for artificial intelligence-enabled devices. The Food and Drug Administration's list reached 1,524 authorised devices by March 2026, with about three quarters in radiology. Authorisation routes include 510(k) clearance, De Novo classification and, increasingly, predetermined change control plans, which the agency finalised in guidance in December 2024. Large health systems, teleradiology groups and imaging chains adopt platforms that host many algorithms, and private payers and Medicare have started to pay for a small number of applications, although most products are paid from operating budgets. Technology companies and imaging equipment makers have large bases in the region, and research hospitals such as Mayo Clinic and Stanford produce evidence and models. Canada follows Health Canada guidance on machine learning-enabled devices and uses artificial intelligence in provincial screening programmes. Challenges include evidence of outcomes, bias monitoring, cybersecurity and the cost of integration, and hospitals increasingly use governance committees before purchase. Evidence remains a theme: studies show that only a small share of authorised tools have randomised trial data, so large buyers ask for local validation, real-world monitoring and clear escalation routes before routine use. Vendors with strong integration and reference sites win most contracts. Europe is a strong adopter that emphasises evidence, data protection and public procurement. Products must obtain a CE mark under the Medical Device Regulation, which treats most diagnostic software as medium or high risk and requires a notified body review. The AI Act adds further duties, although the European Parliament voted in June 2026 for a delay that would move requirements for AI embedded in regulated medical devices to August 2028, subject to Council approval. The General Data Protection Regulation and the European Health Data Space shape data sharing for training. National health services have run large evaluations, including the United Kingdom's artificial intelligence programmes in breast screening, lung cancer and stroke, and Germany and France are expanding reimbursement for digital health applications. Europe is home to Siemens Healthineers, Philips and specialist developers such as Oxipit in Lithuania and Therapixel in France. Language, fragmented procurement and the cost of notified body reviews can slow market entry. Public hospitals tend to buy through tenders that require clinical evidence, interoperability and local support, which favours established vendors with evidence from several countries. Cross-border evidence from several hospitals and clear documentation of intended use are important for tender success, and smaller vendors often partner with equipment makers for distribution. Asia-Pacific is the fastest growing region by volume because large populations, screening programmes and strong technology sectors support rapid deployment. China has many domestic vendors, hospital-based artificial intelligence initiatives and a regulatory system that classifies diagnostic software as a high-risk device, while the largest hospitals use computer vision for chest imaging, lung nodules and eye disease. Japan has an ageing population, high scanner density and a regulatory pathway for software as a medical device, and South Korea has strong domestic firms such as Lunit and Vuno that sell internationally. India's low-cost solutions, such as those from Qure.ai, support tuberculosis and stroke screening, often funded through public programmes and private diagnostic chains. Australia and Singapore have clear guidance on software as a medical device and active public hospital pilots. Southeast Asian countries use mobile and low-cost tools for population screening. Challenges include variation in regulation, data localisation, limited reimbursement and the need to validate models on local populations and scanner mixes. National strategies on digital health and artificial intelligence are expected to keep adoption strong through 2031. Equipment makers, cloud platforms and local start-ups often form joint offers, and government-backed validation programmes help reduce the time needed to gain hospital trust. Latin America is an emerging region where computer vision is used to extend specialist capacity in large and geographically dispersed countries. Brazil is the leading market, with private hospital networks, teleradiology services and the regulator ANVISA treating diagnostic software as medical devices, and national projects use artificial intelligence to support screening in the public system. Mexico, Colombia, Chile and Argentina have active private hospital groups and diagnostic chains adopting cloud-based triage tools, and telehealth companies are testing skin and eye screening on smartphones. Local developers have emerged in areas such as chest imaging and pathology, and global vendors partner with regional distributors. Many public hospitals still use film or older digital systems, and limited broadband in rural areas restricts cloud use. Budget limits, currency changes and import costs are barriers, while privacy laws such as Brazil's General Data Protection Law shape data use. Reimbursement for artificial intelligence is mostly absent. By 2031, growth is likely to depend on modernising picture archiving systems, wider teleradiology and clear regulatory paths that shorten registration times for proven tools. Partnerships with global equipment makers, regional diagnostic chains and telehealth platforms are the typical route to market, since local sales and support matter as much as accuracy. The Middle East and Africa combine well-funded Gulf programmes with limited-resource settings that benefit from tools that extend scarce specialists. Saudi Arabia and the United Arab Emirates have national artificial intelligence strategies, new medical cities and hospital groups that pilot imaging tools, and regulators such as the Saudi Food and Drug Authority have published guidance on software as a medical device. Abu Dhabi has promoted healthcare technology clusters and hospital use of artificial intelligence in screening. Israel is a notable source of start-ups in radiology and cardiology, and Egypt and Jordan have developed imaging services for regional markets. In sub-Saharan Africa, shortages of radiologists are severe, with a small number of specialists per million people in some countries, so portable ultrasound and chest X-ray screening with automated reading are used for tuberculosis and maternal care, often through partnerships with global health agencies. Power supply, connectivity, device maintenance and funding are obstacles, and regulation is still forming. By 2031, growth should come from Gulf hospital upgrades and donor-supported screening programmes that show clear cost and access benefits. Remote reading hubs, portable devices and local training programmes are likely to determine whether tools reach clinics beyond major cities, and whether ministries include them in national screening plans. June 2026: European Parliament backs AI Act delay package: Parliament voted on 16 June 2026 to adopt the digital omnibus agreement, which provisionally moves high-risk duties for AI embedded in medical devices to 2 August 2028, pending Council approval. March 2026: FDA AI-enabled device list reaches 1,524 authorisations: The cumulative list of authorised artificial intelligence-enabled devices stood at 1,524 on 30 March 2026, with radiology accounting for about 76% of entries. January 2025: FDA proposes lifecycle guidance for AI-enabled devices: Draft guidance set out expectations for design, validation, transparency and post-market monitoring of artificial intelligence-enabled device software functions. December 2024: FDA finalises predetermined change control plan guidance: The guidance allows manufacturers of artificial intelligence-enabled devices to agree in advance how models may be modified and retrained without a new submission for each change. November 2024: FDA advisory committee examines generative AI: The Digital Health Advisory Committee discussed the benefits and risks of generative artificial intelligence-enabled devices, including premarket evidence and monitoring needs. Considered in this report • Historic Year: 2020 • Base Year: 2025 • Estimated Year: 2026 • Forecast Year: 2031 Aspects covered in this report • Global Computer Vision in Healthcare Market with its segments and regional outlook • Various drivers and challenges • Ongoing trends and developments • Key developments and regulatory milestones By Component • Software and algorithms • Imaging hardware and cameras • Services By Application • Medical imaging diagnostics • Pathology and digital microscopy • Surgical guidance and robotics • Patient monitoring and safety • Ophthalmology and dermatology screening By Deployment Mode • Cloud • On-premise • Edge and embedded By End User • Hospitals and imaging centres • Diagnostic and pathology laboratories • Ambulatory and specialty clinics • Pharmaceutical, medical technology and research organisations

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Ask an Expert

Sikandar Kesari

Research Analyst

Don't pay for what you don't need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now